Consider BridgeBio Pharma (NASDAQ: BBIO), which reported a hefty $497.49 million in debt in the most recent quarter. Take Halozyme Therapeutics (NASDAQ: HALO) as an example: Its primary line of business is licensing out its drug delivery system and collecting the royalties, which provides it with reliable, repeat returns. In Halozyme's case, existing revenue from technology licensing might be difficult to maintain in the face of inflation, if the terms of the royalties agreements preclude price hikes.